BioCentury
ARTICLE | Company News

ChemoCentryx, Galenica deal

December 30, 2016 9:56 PM UTC

ChemoCentryx and the Vifor Pharma Ltd. subsidiary of Galenica expanded a 2016 deal to include ChemoCentryx candidate CCX140. ChemoCentryx granted Vifor exclusive, worldwide rights, excluding the U.S. and China, to CCX140 to treat rare renal diseases; ChemoCentryx will retain U.S. and China rights. Vifor may opt to obtain worldwide rights to CCX140 for more prevalent forms of chronic kidney disease (CKD), in which case ChemoCentryx would have the option to co-commercialize the candidate in the U.S. CCX140, an inhibitor of CC chemokine receptor 2 (CCR2; CD192), has completed Phase II testing to treat diabetic nephropathy...